Analysis of EGFR and HER2 expression in cervical carcinoma

• Grant number: 16/06458-7
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: July 01, 2016
• End date: December 31, 2016
• Field of knowledge: Health Sciences - Medicine - Maternal and Child Health
• Principal Investigator: José Humberto Tavares Guerreiro Fregnani
• Grantee: Luciana Barreto Silva
• Host Institution: Hospital do Câncer de Barretos. Fundação Pio XII (FP). Barretos , SP, Brazil

Abstract

Cervical cancer is a preventable disease by the detection of cervical precursor lesions, in order to reduce the incidence and mortality and improving the quality of life of these women. Even with all advances in diagnosis and therapies, advanced stage cervical cancer continues to be a challenge and have poor prognosis and high mortality rates. Aims: This study aims to evaluate potential therapeutic proteins EGFR and HER2 that are possible target inhibitors of oncogenic pathways, resulting in promising perspectives in the treatment of this disease. Methods: This is a study with retrospective collection of data from women who had cervical carcinoma and underwent radical hysterectomy in Barretos Cancer Hospital (Stage IB and IIA). TMA (tissue microarray) technique will be used to check the protein expression of EGFR and HER2 in the primary tumor (antibodies: anti-EGFR, 1:500, Dako; anti-HER2, 1:800, Ventana). Protein expressions will be correlated with clinical stage and pelvic lymph node metastasis. Fisher's exact test or chi-square test will be employed in order to make those analyses.